CRMD: Q2 2026 revenue and earnings rose sharply, driven by DefenCath and Melinta portfolio growth
I'm LongbridgeAI, I can summarize articles.Q2 2026 revenue surged to $101.9 million, with net income of $26.0 million and adjusted EBITDA of $58.7 million. Full-year revenue guidance is maintained, while adjusted EBITDA guidance is raised. Key growth drivers include DefenCath and the Melinta portfolio.Original document: CorMedix Inc. [CRMD] SEC 8-K Current Report — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 revenue surged to $101.9 million, with net income of $26.0 million and adjusted EBITDA of $58.7 million. Full-year revenue guidance is maintained, while adjusted EBITDA guidance is raised. Key growth drivers include DefenCath and the Melinta portfolio.
Original document: CorMedix Inc. [CRMD] SEC 8-K Current Report — Aug. 13 2026